Bone Metastases in Prostate Cancer

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[2]  F. Saad,et al.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.

[3]  D. Pastorelli,et al.  Therapeutic management of bone metastasis in prostate cancer: an update , 2016, Expert review of anticancer therapy.

[4]  J. Attia,et al.  Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  F. Saad,et al.  The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[6]  F. Saad,et al.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Rades,et al.  Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Lyman,et al.  Incidence of bone metastases in U.S. patients with solid tumors. , 2016 .

[9]  J. Carles,et al.  Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). , 2016 .

[10]  F. Saad,et al.  Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). , 2016 .

[11]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[12]  H. Shibata,et al.  Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology , 2016, ESMO Open.

[13]  G. Scagliotti,et al.  Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. , 2016, Cancer treatment reviews.

[14]  F. Grossi,et al.  Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers , 2016, Expert review of anticancer therapy.

[15]  Changyin Wang,et al.  Distribution Features of Skeletal Metastases: A Comparative Study between Pulmonary and Prostate Cancers , 2015, PloS one.

[16]  F. Saad,et al.  Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. , 2015, European urology.

[17]  M. Kirienko,et al.  Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. , 2015, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[18]  A. Horwich,et al.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[20]  C. Parker,et al.  Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. , 2015, Critical reviews in oncology/hematology.

[21]  K. Miller,et al.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[22]  Kurt Miller,et al.  Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). , 2015, European urology.

[23]  E. Basch,et al.  Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). , 2015 .

[24]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[25]  M. Agarwal,et al.  Management of skeletal metastases: An orthopaedic surgeon's guide , 2015, Indian journal of orthopaedics.

[26]  Lucy Hanna,et al.  18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry , 2015, The Journal of Nuclear Medicine.

[27]  L. Zeng,et al.  A definition of “uncomplicated bone metastases” based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy , 2015, Journal of bone oncology.

[28]  K. Pittman,et al.  Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  F. Saad,et al.  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). , 2014, European urology.

[30]  W. Heindel,et al.  The diagnostic imaging of bone metastases. , 2014, Deutsches Arzteblatt international.

[31]  J. Beaumont,et al.  Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients. , 2014, Journal of comparative effectiveness research.

[32]  David C. Smith,et al.  Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  E. Basch,et al.  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. , 2014, The Lancet. Oncology.

[35]  T. Brand,et al.  Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. , 2014, Urologic oncology.

[36]  K. Decaestecker,et al.  Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence , 2014, Radiation oncology.

[37]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[38]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Bingshu E. Chen,et al.  Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. , 2014, The Lancet. Oncology.

[40]  E. Basch,et al.  Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[41]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[42]  Lois Lamerato,et al.  Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems , 2013, Supportive Care in Cancer.

[43]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[44]  B. Tombal,et al.  Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  N. Lumen,et al.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. , 2013, Clinical genitourinary cancer.

[46]  M. Morris,et al.  Targeting bone physiology for the treatment of metastatic prostate cancer. , 2013, Clinical advances in hematology & oncology : H&O.

[47]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[48]  Sean S. Park,et al.  Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer , 2013, Front. Oncol..

[49]  E. Basch,et al.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. , 2012, The Lancet. Oncology.

[50]  T. Delea,et al.  Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases , 2012, Prostate Cancer and Prostatic Diseases.

[51]  B. Davis,et al.  Progress in Gene Therapy for Prostate Cancer , 2012, Front. Oncol..

[52]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[53]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[54]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  L. Zeng,et al.  Update on the systematic review of palliative radiotherapy trials for bone metastases. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[56]  K. Pienta,et al.  The prostate cancer bone marrow niche: more than just 'fertile soil'. , 2012, Asian journal of andrology.

[57]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[58]  F. Saad,et al.  Consensus on the utility of bone markers in the malignant bone disease setting. , 2011, Critical reviews in oncology/hematology.

[59]  Heather Payne,et al.  Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. , 2011, Urologic oncology.

[60]  M L Kilgore,et al.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.

[61]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[62]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[63]  E. Mendel,et al.  Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.

[64]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[65]  L. Stalpers,et al.  Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. , 2011, International journal of radiation oncology, biology, physics.

[66]  Peer Eysel,et al.  The treatment of spinal metastases. , 2011, Deutsches Arzteblatt international.

[67]  D. Castellano,et al.  The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain , 2010, European journal of cancer care.

[68]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[69]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[70]  H. Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[71]  V. Fusco,et al.  8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[72]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[73]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[74]  L. Assael,et al.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[75]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  F. Saad,et al.  Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid , 2008, Cancer.

[77]  M. Koutsilieris,et al.  Mechanisms of bone metastasis in prostate cancer: clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[78]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Saad,et al.  Pathologic fractures correlate with reduced survival in patients with malignant bone disease , 2007, Cancer.

[81]  F. Saad,et al.  Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. , 2007, Urology.

[82]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[83]  D. Panicek,et al.  Magnetic resonance imaging of bone marrow in oncology, Part 2 , 2007, Skeletal Radiology.

[84]  M. Rogers,et al.  Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.

[85]  P. Stiff,et al.  Management of the adverse effects associated with intravenous bisphosphonates. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  F. Saad,et al.  Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.

[87]  D. Newling.  Re: Secondary Hormonal Therapy for Advanced Prostate Cancer , 2006 .

[88]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  E. Maranzano,et al.  Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[92]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, New England Journal of Medicine.

[93]  W. Gerald,et al.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.

[94]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[95]  Matthew R. Smith,et al.  Treatment-related osteoporosis in men with prostate cancer , 2004, Clinical Cancer Research.

[96]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[97]  C. Love,et al.  Radionuclide bone imaging: an illustrative review. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[98]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[99]  P. Hoskin,et al.  International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[100]  L. Dogliotti,et al.  Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients. , 2002, The Journal of clinical endocrinology and metabolism.

[101]  H. Koppeschaar,et al.  Analysis of the separate secretion of very low-density lipoprotein (VLDL)-1 and VLDL-2 by the liver will be a principal factor in resolving the proatherogenic lipoprotein profile in hypopituitarism. , 2002, The Journal of clinical endocrinology and metabolism.

[102]  Augusto Caraceni,et al.  Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. , 2002, Journal of pain and symptom management.

[103]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[104]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  S. Larson,et al.  Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[108]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  A. Rezaee,et al.  Nuclear Medicine Modalities to Image Bone Metastases with Bone-Targeting Agents: Conventional Scintigraphy and Positron-Emission Tomography , 2017 .

[110]  F. Bertoldo.  Markers of Bone Turnover in Bone Metastasis from Prostate Cancer , 2017 .

[111]  C. Zoccali,et al.  Surgery: Treatment of Oligometastatic Disease , 2017 .

[112]  J. Petit,et al.  Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. , 2017, Practical radiation oncology.

[113]  M. Picchio,et al.  Detection of Bone Metastases and Evaluation of Therapy Response in Prostate Cancer Patients by Radiolabelled Choline PET/CT , 2017 .

[114]  N. V. As,et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. , 2016, European urology.

[115]  Erin Wong,et al.  Re-irradiation for painful bone metastases - a systematic review. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[116]  Vahid Reza Dabbagh Kakhki,et al.  Pattern and distribution of bone metastases in common malignant tumors. , 2013, Nuclear medicine review. Central & Eastern Europe.

[117]  A. Lipton,et al.  Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. , 2011, Bone.

[118]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[119]  Deepinder P. Singh,et al.  Is there a favorable subset of patients with prostate cancer who develop oligometastases? , 2004, International journal of radiation oncology, biology, physics.